Biogen Announces Bioverativ as Name of New Hemophilia-Focused Company
Biogen announced that Bioverativ will be the name of the standalone, publicly-traded global biotechnology company...
Takeda Receives Marketing Authorization in Canada for NINLARO™ (ixazomib) in Relapsed/Refractory Multiple Myeloma
Takeda Pharmaceutical Company Limited announced Takeda Canada has received approval from Health Canada for NINLARO™...
FDA Approves Mercks KEYTRUDA® for Patients with Recurrent or Metastatic Head and Neck Cancer
Merck known as MSD outside the United States and Canada, announced that the U.S. Food...
Teva Announces Launch of Generic Gleevec® Tablets in the United States
Teva Pharmaceutical Industries Ltd announced the launch of the generic equivalent to Gleevec®1(imatinib mesylate) tablets,100...
Momenta Discontinues Further Accrual of its Phase 2 Trial of Necuparanib
The decision to discontinue enrollment into the study was based on the recommendation...
Novartis CDK4/6 inhibitor LEE011 receives FDA Breakthrough Therapy designation as first-line treatment for advanced...
Novartis announced today that the US FDA has granted Breakthrough Therapy designation to LEE011 (ribociclib),...
Amgen And Advaxis Enter Global Cancer Immunotherapies Collaboration
Amgen and Advaxis, Inc announced a global agreement for the development and commercialization of Advaxis'...
Pfizer and Western Oncolytics Announce Immuno-Oncology Research Collaboration to Investigate Novel Oncolytic Virus Technology
Companies plan to advance Western Oncolytics’ lead preclinical therapy into human testingPotential combination of WO-12...
Economics Drives Thailand led Laboratory Market in ASEAN
Thailand, 2nd largest economy in South East Asia, promotes foreign investment with new S curve...
Janssen Announces Clinical Collaboration with Bristol-Myers Squibb to Evaluate Immuno-oncology Combination in Lung Cancer
Janssen Biotech, Inc. announced it has entered into a clinical study collaboration agreement with Bristol-Myers...
